A PHASE I, OPEN LABEL, NON-RANDOMIZED, SINGLE-DOSE, PARALLEL-COHORT, MATCHED-CONTROL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF AVANAFIL (TA-1790) IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY CONTROL MALE SUBJECTS.
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2011
At a glance
- Drugs Avanafil (Primary)
- Indications Erectile dysfunction
- Focus Pharmacokinetics
- Sponsors VIVUS
- 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.